Jasper Therapeutics, Inc. SEC filings JSPR
Jasper Therapeutics, Inc. has 483 filings in SEC EDGAR's recent list, going back to Sep 13, 2019. Its latest annual report, Form ARS, was filed on Jun 15, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (change to shareholder rights, bylaw or fiscal year change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SC TO-I/A | Amendment no. 1 to form sc to-i | Oct 23, 2026 | — |
| SC TO-I | Form sc to-i | Oct 7, 2026 | — |
| 25-NSE | Delisting notice | Sep 24, 2026 | — |
| D | Filing | Aug 5, 2026 | — |
| EFFECT | Filing | Mar 26, 2025 | — |
| CORRESP | Letter to the SEC | Mar 24, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 21, 2025 | — |
| EFFECT | Filing | May 5, 2023 | — |
| CORRESP | Letter to the SEC | May 3, 2023 | — |
| UPLOAD | Letter from the SEC | May 2, 2023 | — |
| EFFECT | Filing | Oct 18, 2022 | — |
| CORRESP | Letter to the SEC | Oct 14, 2022 | — |
| EFFECT | Filing | Oct 13, 2022 | — |
| UPLOAD | Letter from the SEC | Oct 13, 2022 | — |
| EFFECT | Filing | Mar 29, 2022 | — |
| EFFECT | Filing | Oct 26, 2021 | — |
| CORRESP | Letter to the SEC | Oct 22, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 22, 2021 | — |
| 25-NSE | Delisting notice | Sep 27, 2021 | — |
| 425 | Current report | Sep 20, 2021 | — |
| 425 | Current report | Sep 9, 2021 | — |
| 425 | Form 425 | Sep 8, 2021 | — |
| SEC STAFF LETTER | Filing | Aug 27, 2021 | — |
| EFFECT | Filing | Aug 26, 2021 | — |
| CORRESP | Letter to the SEC | Aug 24, 2021 | — |
| SEC STAFF LETTER | Filing | Aug 24, 2021 | — |
| CORRESP | Letter to the SEC | Aug 20, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 17, 2021 | — |
| CORRESP | Letter to the SEC | Aug 6, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 5, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 3, 2021 | — |
| CORRESP | Letter to the SEC | Jul 22, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 22, 2021 | — |
| CORRESP | Letter to the SEC | Jul 21, 2021 | — |
| CORRESP | Letter to the SEC | Jul 16, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 7, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 6, 2021 | — |
| 425 | Form 425 | Jun 21, 2021 | — |
| 425 | Form 425 | Jun 14, 2021 | — |
| 425 | Form 425 | Jun 9, 2021 | — |
| 425 | Form 425 | Jun 8, 2021 | — |
| 425 | Form 425 | Jun 1, 2021 | — |
| 425 | Form 425 | May 26, 2021 | — |
| 425 | Form 425 | May 19, 2021 | — |
| NT 10-Q | Notification of late filing | May 18, 2021 | Mar 31, 2021 |
| 425 | Current report | May 7, 2021 | — |
| 425 | Current report | May 6, 2021 | — |
| CERT | Filing | Nov 20, 2019 | — |
| EFFECT | Filing | Nov 19, 2019 | — |
| 8-A12B | For registration of certain classes of securities | Nov 18, 2019 | — |
| CORRESP | Letter to the SEC | Nov 18, 2019 | — |
| CORRESP | Letter to the SEC | Nov 18, 2019 | — |
| CORRESP | Letter to the SEC | Nov 14, 2019 | — |
| UPLOAD | Letter from the SEC | Nov 14, 2019 | — |
| CORRESP | Letter to the SEC | Oct 25, 2019 | — |
| UPLOAD | Letter from the SEC | Oct 9, 2019 | — |
| DRS | Filing | Sep 13, 2019 | — |
Showing 57 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- JSPR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Redwood City, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1788028
- Former names
- Amplitude Healthcare Acquisition Corp (until Sep 29, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.